Treace Medical Concepts, Inc. revised earnings guidance for the full-year 2024. The company now expected full-year 2024 revenue of $201 million to $211 million, representing growth of 7% to 13%, compared to full-year 2023. This compares to previous guidance of $220 million to $225 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.35 USD | +0.38% | -10.42% | -58.20% |
May. 17 | North American Morning Briefing : The "Everything -2- | DJ |
May. 16 | UBS Downgrades Treace Medical Concepts to Neutral From Buy, Cuts Price Target to $6.50 From $16 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-58.20% | 330M | |
+75.28% | 12.54B | |
-20.90% | 7.71B | |
+8.01% | 6.72B | |
+12.49% | 5.38B | |
+37.02% | 4.89B | |
-17.23% | 4.71B | |
-25.08% | 3.75B | |
-26.57% | 2.77B | |
+58.74% | 2.55B |
- Stock Market
- Equities
- TMCI Stock
- News Treace Medical Concepts, Inc.
- Treace Medical Concepts, Inc. Revises Earnings Guidance for the Full-Year 2024